A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-60
SponsorPeking University People's Hospital
About this trial
The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.
Eligibility criteria
Qualifiers
Severe aplastic anemia;
Aged 40-60 years old;
Weight 45Kg-100Kg;
Eastern Cooperative Oncology Group (ECOG) score ≤3;
Disqualifiers
With other hematologic diseases;
Expected survival of less than 1 month;
Previous autologous or allogeneic hematopoietic stem cell transplantation;
Pregnant patients;
Trial design
Treatments tested in this trial
- BFCA conditiong regimen
Treatment groups
64 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov